Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry
Overview
Authors
Affiliations
Introduction: A new generation of hemodialysis (HD) membranes called medium cut-off (MCO) membranes possesses enhanced capacities for middle molecule clearance, which have been associated with adverse outcomes in this population. These improvements could potentially positively impact patient-reported outcomes (PROs).
Objective: The objective of this study was to evaluate the impact of MCO membranes on PROs in a cohort of HD patients in Colombia.
Methods: This was a prospective, multicenter, observational cohort study of 992 patients from 12 renal clinics in Colombia who were switched from high-flux HD to MCO therapy and observed for 12 months. Changes in Kidney Disease Quality of Life 36-Item Short Form Survey (KDQoL-SF36) domains, Dialysis Symptom Index (DSI), and restless legs syndrome (RLS) 12 months after switching to MCO membranes were compared with time on high-flux membranes. Repeated measures of ANOVA were used to evaluate changes in KDQoL-SF36 scores; severity scoring was used to assess DSI changes over time; Cochran's Q test was used to evaluate changes in frequency of diagnostic criteria of RLS.
Results: During 12 months of follow-up, 3 of 5 KDQoL-SF36 domains improved compared with baseline: symptoms (p < 0.0001), effects of kidney disease (p < 0.0001), and burden of kidney disease (p < 0.001). The proportion of patients diagnosed with RLS significantly decreased from 22.1% at baseline to 10% at 12 months (p < 0.0001). No significant differences in the number of symptoms (DSI, p = 0.1) were observed, although their severity decreased (p = 0.009).
Conclusions: In conventional HD patients, the expanded clearance of large middle molecules with MCO-HD membranes was associated with higher health-related quality of life scores and a decrease in the prevalence of RLS.
Marcello M, Marturano D, Ronco C, Zanella M Clin Kidney J. 2024; 17(9):sfae266.
PMID: 39319306 PMC: 11420667. DOI: 10.1093/ckj/sfae266.
Valderrama-Rios M, Sanchez R, Sanabria M Int Urol Nephrol. 2024; 56(7):2337-2350.
PMID: 38376660 PMC: 11190008. DOI: 10.1007/s11255-024-03940-x.
Intradialytic Tolerance and Recovery Time in Different High-Efficiency Hemodialysis Modalities.
Zakrzewska A, Biedunkiewicz J, Komorniczak M, Jankowska M, Jasiulewicz K, Plonka N J Clin Med. 2024; 13(2).
PMID: 38256460 PMC: 10816973. DOI: 10.3390/jcm13020326.
Medium cut-off dialyzer for middle molecular uremic toxins in AKI and chronic dialysis.
Fiorentino M, La Fergola F, De Rosa S J Nephrol. 2023; 37(1):23-37.
PMID: 37843731 PMC: 10920419. DOI: 10.1007/s40620-023-01771-0.
Ruseckaite R, Mudunna C, Caruso M, Ahern S Health Qual Life Outcomes. 2023; 21(1):71.
PMID: 37434146 PMC: 10337187. DOI: 10.1186/s12955-023-02155-5.